Zhi Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhi Xiao has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Shouman Wang
16 shared publicationsNianhua Ding
Department of Clinical Laboratory, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China
11 shared publicationsJuan Huang
Breast Cancer Center, Department of General Surgery, Xiangya Hospital, Central South University, Changsha, People’s Republic of China
7 shared publicationsJian Pang
Department of General Surgery, the Second Xiangya Hospital, Central South University, Changsha, China
6 shared publicationsXue Dong
Subspecialty Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China
6 shared publicationsJiaqi Yuan
Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China
5 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 129
Severe radiodermatitis and implant loss associated with pembrolizumab and olaparib following pre-pectoral breast reconstruction in a 31-year-old female: a case report
Background: Endoscopic nipple-sparing mastectomy (E-NSM) with immediate implant reconstruction is increasingly adopted to preserve breast appearance and quality of life. Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have substantially improved survival in BRCA-mutated triple-negative breast cancer (TNBC). However, the safety of sequential olaparib following concurrent pembrolizumab and radiotherapy in patients with pre-pectoral breast reconstruction remains poorly defined, and the risk of severe cutaneous toxicity and implant loss is underrecognized. Case Description: We herein report the case of a 31-year-old female who presented with a chief complaint of palpable masses in the left breast and ipsilateral axilla. Diagnostic core needle biopsies of the primary breast lesion and axillary lymph node were conducted, and histopathological examination confirmed invasive TNBC with ipsilateral axillary lymph node metastasis. Germline genetic testing further revealed a pathogenic BRCA1 mutation. After completion of multidisciplinary neoadjuvant systemic therapy, the patient underwent E-NSM with immediate pre-pectoral prosthetic breast reconstruction. Postoperatively, the patient received adjuvant pembrolizumab followed by locoregional radiotherapy. Although only grade 2 radiodermatitis (RD) was initially observed, the subsequent initiation of adjuvant olaparib triggered a rapid and catastrophic clinical deterioration. Within one week of commencing olaparib, the patient’s condition progressed to grade 4 severe RD, characterized by extensive full-thickness skin necrosis and eventual implant extrusion, necessitating surgical explantation. Conclusions: This case highlights catastrophic synergistic cutaneous toxicity and implant loss caused by the sequential combination of pembrolizumab, radiotherapy, and olaparib in patients with pre-pectoral breast reconstruction. Olaparib serves as the dominant pathogenic factor, delivering a lethal “second hit” by inhibiting DNA repair in radiation-sensitized, hypovascular skin flaps overlying the implant. Weekly skin toxicity monitoring is mandatory from the initiation of radiotherapy until at least 2 months after the completion of radiotherapy. Pembrolizumab and olaparib should be initiated only after a mandatory washout period of 2 months following the end of radiotherapy, with monitoring performed every 1 to 2 weeks throughout the treatment course. No additional systemic anti-tumor agents shall be administered concurrently with radiotherapy. Upon detection of early skin reactions, prompt intervention with topical corticosteroids and temporary olaparib interruption is indicated, tailored to toxicity severity.
- 1 July 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 129
Open AccessSevere radiodermatitis and implant loss associated with pembrolizumab and olaparib following pre-pectoral breast reconstruction in a 31-year-old female: a case report
Background: Endoscopic nipple-sparing mastectomy (E-NSM) with immediate implant reconstruction is increasingly adopted to preserve breast appearance and quality of life. Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have substantially improved survival in BRCA-mutated triple-negative breast cancer (TNBC). However, the safety of sequential olaparib following concurrent pembrolizumab and radiotherapy in patients with pre-pectoral breast reconstruction remains poorly defined, and the risk of severe cutaneous toxicity and implant loss is underrecognized. Case Description: We herein report the case of a 31-year-old female who presented with a chief complaint of palpable masses in the left breast and ipsilateral axilla. Diagnostic core needle biopsies of the primary breast lesion and axillary lymph node were conducted, and histopathological examination confirmed invasive TNBC with ipsilateral axillary lymph node metastasis. Germline genetic testing further revealed a pathogenic BRCA1 mutation. After completion of multidisciplinary neoadjuvant systemic therapy, the patient underwent E-NSM with immediate pre-pectoral prosthetic breast reconstruction. Postoperatively, the patient received adjuvant pembrolizumab followed by locoregional radiotherapy. Although only grade 2 radiodermatitis (RD) was initially observed, the subsequent initiation of adjuvant olaparib triggered a rapid and catastrophic clinical deterioration. Within one week of commencing olaparib, the patient’s condition progressed to grade 4 severe RD, characterized by extensive full-thickness skin necrosis and eventual implant extrusion, necessitating surgical explantation. Conclusions: This case highlights catastrophic synergistic cutaneous toxicity and implant loss caused by the sequential combination of pembrolizumab, radiotherapy, and olaparib in patients with pre-pectoral breast reconstruction. Olaparib serves as the dominant pathogenic factor, delivering a lethal “second hit” by inhibiting DNA repair in radiation-sensitized, hypovascular skin flaps overlying the implant. Weekly skin toxicity monitoring is mandatory from the initiation of radiotherapy until at least 2 months after the completion of radiotherapy. Pembrolizumab and olaparib should be initiated only after a mandatory washout period of 2 months following the end of radiotherapy, with monitoring performed every 1 to 2 weeks throughout the treatment course. No additional systemic anti-tumor agents shall be administered concurrently with radiotherapy. Upon detection of early skin reactions, prompt intervention with topical corticosteroids and temporary olaparib interruption is indicated, tailored to toxicity severity.
- Open Access
- 19 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 865-872
Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study
Background: To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib, and CDK4/6 inhibitor dalpiciclib in patients with hormone receptor-negative/HER2-positive (HR-HER2+) early breast cancer (EBC). Materials and Methods: This open-label, single-arm, phase II study was designed using the Simon two-stage method (Registration Number: Chi-CTR-2200060748). Patients with operable HR-HER2+ EBC (T1-3 and N0–2) were enrolled. Eligible patients received trastuzumab (HLX02, 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks intravenously), pyrotinib (400 mg daily orally), and dalpiciclib (125 mg daily orally for 3 weeks, followed by 1 week off) for 16 weeks. Surgery was performed 3–6 weeks after the completion of drug treatment. The primary endpoint was total pathological complete response (tpCR, ypT0/Tis, and ypN0) rates at surgery, and secondary endpoints included breast pCR (bpCR) rates (ypT0/Tis), residual cancer burden (RCB), objective response rate (ORR), change of Ki-67 scores, survival, and safety. Results: Between June 2022 and June 2024, a total of 34 patients with a median age of 55 years (range: 35–67) were enrolled. Thirty patients received all cycles of treatment and underwent surgery with a median follow-up of 20 months. The tpCR was achieved in 19 patients (63.3%; 95% CI, 45.5–78.1%). The bpCR was 66.7% (20/30). The number of patients with RCB-0 or RCB-I was 22 (73.3%). The most common Grade 3 treatment-related adverse events were diarrhea (50.0%), neutropenia (20.6%), and leukopenia (17.7%). No Grade 4 events or treatment-related deaths occurred. Conclusion: In patients with HR-HER2+ EBC, the neoadjuvant therapy with trastuzumab, pyrotinib, and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.
- 19 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 865-872
Open AccessEfficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study
Background: To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib, and CDK4/6 inhibitor dalpiciclib in patients with hormone receptor-negative/HER2-positive (HR-HER2+) early breast cancer (EBC). Materials and Methods: This open-label, single-arm, phase II study was designed using the Simon two-stage method (Registration Number: Chi-CTR-2200060748). Patients with operable HR-HER2+ EBC (T1-3 and N0–2) were enrolled. Eligible patients received trastuzumab (HLX02, 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks intravenously), pyrotinib (400 mg daily orally), and dalpiciclib (125 mg daily orally for 3 weeks, followed by 1 week off) for 16 weeks. Surgery was performed 3–6 weeks after the completion of drug treatment. The primary endpoint was total pathological complete response (tpCR, ypT0/Tis, and ypN0) rates at surgery, and secondary endpoints included breast pCR (bpCR) rates (ypT0/Tis), residual cancer burden (RCB), objective response rate (ORR), change of Ki-67 scores, survival, and safety. Results: Between June 2022 and June 2024, a total of 34 patients with a median age of 55 years (range: 35–67) were enrolled. Thirty patients received all cycles of treatment and underwent surgery with a median follow-up of 20 months. The tpCR was achieved in 19 patients (63.3%; 95% CI, 45.5–78.1%). The bpCR was 66.7% (20/30). The number of patients with RCB-0 or RCB-I was 22 (73.3%). The most common Grade 3 treatment-related adverse events were diarrhea (50.0%), neutropenia (20.6%), and leukopenia (17.7%). No Grade 4 events or treatment-related deaths occurred. Conclusion: In patients with HR-HER2+ EBC, the neoadjuvant therapy with trastuzumab, pyrotinib, and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.
- 10 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 2110-2111
ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer
- 10 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 2110-2111
ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer
- 20 November 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (2) , 750-759
Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials
The systemic immune-inflammation index (SII) is a hematological marker that reflects the immune status of the body. This study was designed to evaluate the
- 20 November 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (2) , 750-759
Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials
The systemic immune-inflammation index (SII) is a hematological marker that reflects the immune status of the body. This study was designed to evaluate the
- Open Access
- 19 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy
The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its potential value to distinguish patients who may benefit from trastuzumab therapy, warrant further investigation. Clinical data was collected from 797 HER-2-positive BC patients between July 2013 and March 2018. Baseline data differences were adjusted with propensity score matching. Univariate and multivariate analyses explored the correlation between clinical pathological factors, SII, and DFS. Four groups were established. Based on the baseline SII values of the participants, patients who did not receive trastuzumab treatment were divided into Group 1 (Low-SII) and Group 2 (High-SII), where SII had no predictive value for prognosis between groups. Participants who received trastuzumab treatment were also divided into two groups: the Low-SII group (Group 3) and the High-SII group (Group 4). The 5-year DFS was significantly higher in Group 3 than in Group 4 (91.76% vs. 82.76%, P = 0.017). Furthermore, multivariate analysis demonstrated a significant association between high SII and shorter DFS (HR = 3.430, 95% CI = 1.830–6.420, P < 0.001). In HER-2-positive BC patients treated with trastuzumab, those with lower SII showed a longer DFS, suggesting that SII may help in identifying patients who benefit from trastuzumab therapy.
- 19 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessSystemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy
The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its potential value to distinguish patients who may benefit from trastuzumab therapy, warrant further investigation. Clinical data was collected from 797 HER-2-positive BC patients between July 2013 and March 2018. Baseline data differences were adjusted with propensity score matching. Univariate and multivariate analyses explored the correlation between clinical pathological factors, SII, and DFS. Four groups were established. Based on the baseline SII values of the participants, patients who did not receive trastuzumab treatment were divided into Group 1 (Low-SII) and Group 2 (High-SII), where SII had no predictive value for prognosis between groups. Participants who received trastuzumab treatment were also divided into two groups: the Low-SII group (Group 3) and the High-SII group (Group 4). The 5-year DFS was significantly higher in Group 3 than in Group 4 (91.76% vs. 82.76%, P = 0.017). Furthermore, multivariate analysis demonstrated a significant association between high SII and shorter DFS (HR = 3.430, 95% CI = 1.830–6.420, P < 0.001). In HER-2-positive BC patients treated with trastuzumab, those with lower SII showed a longer DFS, suggesting that SII may help in identifying patients who benefit from trastuzumab therapy.
- Top Cited PapersOpen Access
- 4 March 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (6) , 419-440
Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1
Tumor-resident microbiota in breast cancer promote cancer initiation and malignant progression. However, targeting microbiota to improve the effects of breast cancer therapy has not been investigated in detail. Here, we evaluated the microbiota composition of breast tumors and found that enterotoxigenic Bacteroides fragilis (ETBF) was highly enriched in the tumors of patients who did not respond to taxane-based neoadjuvant chemotherapy. ETBF, albeit at low biomass, secreted the toxic protein BFT-1 to promote breast cancer cell stemness and chemoresistance. Mechanistic studies showed that BFT-1 directly bound to NOD1 and stabilized NOD1 protein. NOD1 was highly expressed on ALDH+ breast cancer stem cells (BCSCs) and cooperated with GAK to phosphorylate NUMB and promote its lysosomal degradation, thereby activating the NOTCH1-HEY1 signaling pathway to increase BCSCs. NOD1 inhibition and ETBF clearance increases the chemosensitivity of breast cancer by impairing BCSCs.
- 4 March 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (6) , 419-440
Top Cited PapersOpen AccessMicrobiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1
Tumor-resident microbiota in breast cancer promote cancer initiation and malignant progression. However, targeting microbiota to improve the effects of breast cancer therapy has not been investigated in detail. Here, we evaluated the microbiota composition of breast tumors and found that enterotoxigenic Bacteroides fragilis (ETBF) was highly enriched in the tumors of patients who did not respond to taxane-based neoadjuvant chemotherapy. ETBF, albeit at low biomass, secreted the toxic protein BFT-1 to promote breast cancer cell stemness and chemoresistance. Mechanistic studies showed that BFT-1 directly bound to NOD1 and stabilized NOD1 protein. NOD1 was highly expressed on ALDH+ breast cancer stem cells (BCSCs) and cooperated with GAK to phosphorylate NUMB and promote its lysosomal degradation, thereby activating the NOTCH1-HEY1 signaling pathway to increase BCSCs. NOD1 inhibition and ETBF clearance increases the chemosensitivity of breast cancer by impairing BCSCs.
- Open Access
- 11 January 2024
- Published by Springer Nature in Breast Cancer Research
- Vol. 26 (1) , 1-10
Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial
Purpose: This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Experimental design: Data from 780 patients from the CLEOPATRA trial and 248 local patients were collected. Patients were divided into the low and high NLR subgroups by the NLR cutoff value. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) methods were used to control bias. Associations between the NLR and progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The baseline characteristics of the subgroups were well balanced after PSM and IPTW. A low baseline NLR was associated with better PFS and OS in the trastuzumab and docetaxel (TH) group in the unadjusted, PSM and IPTW models. After IPTW, a low NLR, versus a high NLR, was associated with improved PFS (HR 1.35, 95% CI 1.07–1.70, P = 0.012) and OS (HR 1.47, 95% CI 1.12–1.94, P = 0.006) in the TH group. In patients undergoing treatment with trastuzumab and pertuzumab and docetaxel (THP), a low baseline NLR was also correlated with better PFS but not OS across the three models. After IPTW, a low NLR was associated with better PFS (HR 1.52, 95% CI 1.20–1.93, P = 0.001) than a high NLR in the THP group. Multivariate analyses showed that a low baseline NLR was a predictor for PFS and OS in the TH group and for PFS in the THP group in all three models. In the real-world setting, a low baseline NLR was a predictor of better PFS among patients treated with docetaxel plus trastuzumab without or with pertuzumab in the multivariate model (P = 0.015 and 0.008, respectively). Conclusions: A low baseline NLR is associated with better survival outcomes among HER2-positive MBC patients receiving docetaxel plus trastuzumab/pertuzumab as first-line therapy.
- 11 January 2024
- Published by Springer Nature in Breast Cancer Research
- Vol. 26 (1) , 1-10
Open AccessPrognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial
Purpose: This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Experimental design: Data from 780 patients from the CLEOPATRA trial and 248 local patients were collected. Patients were divided into the low and high NLR subgroups by the NLR cutoff value. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) methods were used to control bias. Associations between the NLR and progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The baseline characteristics of the subgroups were well balanced after PSM and IPTW. A low baseline NLR was associated with better PFS and OS in the trastuzumab and docetaxel (TH) group in the unadjusted, PSM and IPTW models. After IPTW, a low NLR, versus a high NLR, was associated with improved PFS (HR 1.35, 95% CI 1.07–1.70, P = 0.012) and OS (HR 1.47, 95% CI 1.12–1.94, P = 0.006) in the TH group. In patients undergoing treatment with trastuzumab and pertuzumab and docetaxel (THP), a low baseline NLR was also correlated with better PFS but not OS across the three models. After IPTW, a low NLR was associated with better PFS (HR 1.52, 95% CI 1.20–1.93, P = 0.001) than a high NLR in the THP group. Multivariate analyses showed that a low baseline NLR was a predictor for PFS and OS in the TH group and for PFS in the THP group in all three models. In the real-world setting, a low baseline NLR was a predictor of better PFS among patients treated with docetaxel plus trastuzumab without or with pertuzumab in the multivariate model (P = 0.015 and 0.008, respectively). Conclusions: A low baseline NLR is associated with better survival outcomes among HER2-positive MBC patients receiving docetaxel plus trastuzumab/pertuzumab as first-line therapy.
- 1 December 2021
- Published by Elsevier in Clinical Breast Cancer
- Vol. 21 (6) , e681-e687
Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
- 1 December 2021
- Published by Elsevier in Clinical Breast Cancer
- Vol. 21 (6) , e681-e687
Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
- Open Access
- 30 May 2021
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 15 (1) , 1-6
A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report
Background: CD74-ROS1 fusion genes have been detected in non-small cell lung carcinomas (NSCLC), but not in inflammatory breast cancer. Case presentation: Herein, we report a CD74-ROS1 fusion gene identified in a 64-year-old Chinese woman with inflammatory breast cancer (IBC). The patient initially presented with a rapidly growing mass in the left breast with diffuse erythema developing over a period of 2 months. Diagnosis of invasive breast carcinoma was made by core needle biopsy. Positron emission tomography-computed tomography (PET/CT) demonstrated multiple organ metastases. Genomic DNA was extracted from tumor tissue and analyzed using next-generation sequencing (NGS). The CD74-ROS1 fusion gene was detected in the genomic DNA. The patient refused crizotinib treatment, and could not tolerate the side effects of palliative chemotherapy. Unfortunately, the patient died 4 months after diagnosis. Conclusion: We report the case of a CD74-ROS1 fusion gene in a patient with IBC. This may reveal, for the first time, a possible association between CD74-ROS1 gene fusion and rapid progression of inflammatory breast cancer. Multigene panel testing can be performed when rapidly progressive breast cancer occurs and could reveal potential therapeutic strategies.
- 30 May 2021
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 15 (1) , 1-6
Open AccessA novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report
Background: CD74-ROS1 fusion genes have been detected in non-small cell lung carcinomas (NSCLC), but not in inflammatory breast cancer. Case presentation: Herein, we report a CD74-ROS1 fusion gene identified in a 64-year-old Chinese woman with inflammatory breast cancer (IBC). The patient initially presented with a rapidly growing mass in the left breast with diffuse erythema developing over a period of 2 months. Diagnosis of invasive breast carcinoma was made by core needle biopsy. Positron emission tomography-computed tomography (PET/CT) demonstrated multiple organ metastases. Genomic DNA was extracted from tumor tissue and analyzed using next-generation sequencing (NGS). The CD74-ROS1 fusion gene was detected in the genomic DNA. The patient refused crizotinib treatment, and could not tolerate the side effects of palliative chemotherapy. Unfortunately, the patient died 4 months after diagnosis. Conclusion: We report the case of a CD74-ROS1 fusion gene in a patient with IBC. This may reveal, for the first time, a possible association between CD74-ROS1 gene fusion and rapid progression of inflammatory breast cancer. Multigene panel testing can be performed when rapidly progressive breast cancer occurs and could reveal potential therapeutic strategies.